Brief: Firebrick Pharma Says Firebrick COVID-19 Trial Achieves Primary Endpoint
07/08/2023 02:39
Aug 7 (Reuters) - Firebrick Pharma Ltd FRE.AX :
* FIREBRICK COVID-19 TRIAL ACHIEVES PRIMARY ENDPOINT
* PHASE 2 TRIAL OF NASODINE NASAL SPRAY IN COVID-19 ACHIEVED
ITS
PRIMARY ENDPOINT
Source text for Eikon: ID:nASX4F6z6H
Further company coverage: FRE.AX
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Firebrick Pharma
See all newsAustralia's Firebrick Pharma jumps on plan to launch Nasodine products in US retail market
Brief: Firebrick Pharma Receives A$293,000 Research And Development Tax Incentive
Brief: Firebrick Pharma Says Nasodine Composition Patent Granted In New Zealand
Brief: Firebrick Pharma Says Nasodine Patent Accepted In Canada
Brief: Firebrick Pharma Secures A$1.5 Million Via Placement